Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents

Area of Science:

• Oncology
• Clinical Pharmacology

Background:

• Molecularly targeted agents have revolutionized cancer treatment, altering clinical practice.
• These agents differ from traditional cytotoxic drugs in administration, toxicity, and efficacy assessment.
• Combinations of targeted agents or targeted agents with cytotoxic drugs are increasingly used due to single-agent limitations.

Purpose of the Study:

• To review the challenges in the early clinical development of novel anticancer agents in the era of molecularly targeted therapies.
• To focus on critical aspects of phase I oncology clinical trials, including endpoint selection and dose escalation strategies.

Main Methods:

• Review of current literature and practices in early-phase oncology clinical trials.
• Emphasis on dose escalation methods specifically for molecularly targeted agents and combination therapies.
• Discussion of endpoint selection in phase I trials for novel anticancer agents.

Main Results:

• Early clinical development of molecularly targeted agents requires adapted trial designs.
• Endpoint selection in phase I trials needs to reflect the unique characteristics of targeted agents.
• Specific dose escalation methods are necessary for molecularly targeted agents and their combinations.

Conclusions:

• Adapting phase I trial designs is crucial for the successful development of molecularly targeted anticancer agents.
• Optimized dose escalation and endpoint selection are key to efficiently evaluating these novel therapies.
• Addressing these challenges will accelerate the delivery of effective targeted treatments to cancer patients.